Ispire Technology Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $81.4M
- Price
- $1.41
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.02%
- Volume
- 53.4K
About
Ispire Technology Inc. is a company that specializes in the production of electronic cigarettes and cannabis-related vaping devices. Established in 2019, its primary operational base is located in Los Angeles, California. The firm operates as a subsidiary under the corporate umbrella of Pride Worldwide Investment Limited.
Quick stats
Shares outstanding57.8M
Computed float21.2M
Float / shares36.8%
Key info
SectorConsumer Defensive
IndustryTobacco
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001948455
AI Summary
AI-generated1/10
minorbullishproduct launch
IKE Tech Launches IKE 2.0 to Bring Continuous Compliance to Regulated Products
IKE Tech LLC — a joint venture among Ispire Technology (NASDAQ: ISPR), Berify, and Chemular — launched IKE 2.0, a continuous-compliance platform for regulated products initially focused on the global nicotine category.
The platform connects identity verification, product authentication, configurable policy enforcement and analytics across the product life cycle, and is protected by 11 issued patents with SOC 2 Type II certification.
The underlying age-verification technology has an FDA PMTA accepted for review since 2025; in a controlled Human Factors Study of 102 participants it prevented underage device activation in every attempted case, with 91% adult ease-of-use and a sub-1% error rate.
For ISPR, this is incremental progress at its JV, not a direct revenue event; IKE Tech also plans to extend into cannabis, healthcare, gaming and other regulated categories.
Red flags
- Human Factors Study has not been peer-reviewed; controlled findings may not translate to real-world outcomes
- FDA acceptance for PMTA review is not a marketing authorization; review remains ongoing
- Impact on ISPR is indirect via unconsolidated JV; no revenue or financial terms disclosed